Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TLC-2716
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : OrsoBio
Deal Size : Undisclosed
Deal Type : Acquisition
Details : TLC-2716 is a liver-targeted, inverse agonist of LXR that regulates plasma triglycerides and cholesterol via multiple mechanisms, including inhibition of DNL, increased clearance of triglyceride- and cholesterol-rich lipoproteins, and reduced intestinal ...
Brand Name : TLC-2716
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 02, 2022
Lead Product(s) : TLC-2716
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : OrsoBio
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?